Canterbury DHB


Acute Lymphoblastic Leukaemia

This section was reviewed by Dr Peter Ganly in November 2018. The next review date is November 2021.

See a summary of changes.

In This Section


Clinical Features

Laboratory Diagnosis

Prognosis, Risk Factors and the Decision to Treat

Pre-Treatment Investigations for New ALL and Burkitt's Lymphoma Patients


About this Canterbury DHB document (4398):

Document Owner:

Peter Ganly (see Who's Who)

Last Reviewed:

November 2018

Next Review:

November 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 4398